Company: CYTK
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013167
Chunk: 26

Company: CYTOKINETICS INC
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 26
---
 LLC (“Jefferies”) (described below) and the proposed increase in the aggregate number of shares of Common Stock that may be issued under the 2004 EIP, as amended and restated assuming Proposal 2 is approved by our stockholders, we have no definitive plan, arrangement, or understanding to issue the additional shares of Common Stock. The additional shares of Common Stock will be available for issuance by our Board of Directors for various corporate purposes, including but not limited to, grants under employee stock plans, financings, potential strategic transactions, including mergers, acquisitions, strategic partnerships, joint ventures, divestitures, business combinations, stock splits, stock dividends, as well as other general corporate transactions. If the authorization of an increase in the available Common Stock is postponed until the foregoing specific needs arise, the delay and expense incident to obtaining approval of the stockholders at that time could impair our ability to achieve the corporate purposes set forth above. In addition to the broader rationale noted above, in February 2025, we entered into a Controlled Equity Offering Sales Agreement (the “Sales Agreement”) with Jefferies, under which we may offer and sell, from time to time at our sole discretion, shares of the Common Stock having an aggregate offering price of up to $500.0 million through Jefferies, as sales agent. As of March 31, 2025, approximately $500 million of Common Stock remains available to be sold under the Sales Agreement. In addition, as described in Proposal 2, our Board of Directors has approved, subject to stockholder approval at the Annual Meeting, an increase of 5,000,000 shares of Common Stock to be reserved for issuance under the 2004 EIP. A portion of the authorized share increase may be used for the reservation of such additional shares for issuance under the 2004 EIP.

| 16 |     | Cytokinetics, Inc.|2025 Proxy Statement |

TABLE OF CONTENTS PROPOSAL THREE

The Restated Certificate currently authorizes the issuance of up to 163,000,000 shares of our Common Stock. As of March 31, 2025, 119,220,302 shares of Common Stock were outstanding. In addition, as of March 31, 2025, the Company had 14,211,972 shares of Common Stock subject to outstanding equity awards and 12,575,000 shares of Common Stock reserved for issuance upon conversion of the Company’s outstanding convertible notes. Accordingly, the Company had